Results 131 to 140 of about 4,537,045 (350)

EMT‐associated bias in the Parsortix® system observed with pancreatic cancer cell lines

open access: yesMolecular Oncology, EarlyView.
The Parsortix® system was tested for CTC enrichment using pancreatic cancer cell lines with different EMT phenotypes. Spike‐in experiments showed lower recovery of mesenchymal‐like cells. This was confirmed with an EMT‐inducible breast cancer cell line.
Nele Vandenbussche   +8 more
wiley   +1 more source

Retracted: Building Construction Design Based on Particle Swarm Optimization Algorithm

open access: yesJournal of Control Science and Engineering, 2023
Journal of Control Science and Engineering
doaj   +1 more source

Tumor clusters with divergent inflammation and human retroelement expression determine the clinical outcome of patients with serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Analysis of treatment‐naïve high‐grade serous ovarian carcinoma (HGSOC) and control tissues for ERVs, LINE‐1 (L1), inflammation, and immune checkpoints identified five clusters with diverse patient recurrence‐free survivals. An inflammation score was calculated and correlated with retroelement expression, where one novel cluster (Triple‐I) with high ...
Laura Glossner   +6 more
wiley   +1 more source

Retracted: Intelligent Analysis of Logistics Information Based on Network Dynamic Data

open access: yesJournal of Control Science and Engineering, 2023
Journal of Control Science and Engineering
doaj   +1 more source

Morphology Under Control: Engineering Biodegradable Stomatocytes. [PDF]

open access: yesACS Macro Lett, 2017
Pijpers IAB   +3 more
europepmc   +1 more source

Towards a methodology for rigorous development of generic requirements patterns

open access: yes, 2005
We present work in progress on a methodology for the engineering, validation and verification of generic requirements using domain engineering and formal methods.
Johnson, Ian   +2 more
core  

EGFR‐STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1‐positive prostate cancer

open access: yesMolecular Oncology, EarlyView.
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy